Drug
Gemtuzumab clinical trials
Also written Mylotarg, CMA-676 and CDP-771.
- studies test it
- 73
- open now
- 10
- in phase 3
- 14
- first study started
- 2000
Keep track of what changes. Save the Gemtuzumab studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Name
Brand
- Mylotarg
- 43
Studies by the year they started
72 studies that test it; most in 2019 (9)
| Year | Studies |
|---|---|
| 2000 | 5 |
| 2001 | 3 |
| 2002 | 6 |
| 2003 | 4 |
| 2004 | 8 |
| 2005 | 3 |
| 2006 | 3 |
| 2007 | 4 |
| 2008 | 4 |
| 2009 | 3 |
| 2010 | 1 |
| 2011 | 2 |
| 2012 | 2 |
| 2015 | 1 |
| 2016 | 1 |
| 2017 | 1 |
| 2018 | 3 |
| 2019 | 9 |
| 2020 | 3 |
| 2021 | 2 |
| 2023 | 2 |
| 2025 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 25
- Phase 2
- 46
- Phase 3
- 14
- Phase 4
- 3
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 9 · Other 64
M.D. Anderson Cancer Center (10) · Wyeth is now a wholly owned subsidiary of Pfizer (5) · Fred Hutchinson Cancer Center (4) · European Organisation for Research and Treatment of Cancer - EORTC (4) · National Cancer Institute (NCI) (3) · New York Medical College (3) · SWOG Cancer Research Network (3) · Children's Oncology Group (3)
Often tested with
Tested in the same studies.
Cytarabine (10) · Fludarabine (5) · Mitoxantrone (5) · Azacitidine (4) · Daunorubicin (4) · CPX-351 (4) · Venetoclax (4) · Busulfan (3)
Studies
Open first, then newest update. How each study uses Gemtuzumab is read from its arms, and is right about nine times in ten.
Testing it · 73
- Testing the Addition of Venetoclax or Gemtuzumab Ozogamicin (GO) to Usual Treatment Regimen (Cytarabine and Daunorubicin, "7+3") for Core Binding Factor Acute Myeloid Leukemia (CBF-AML) to Improve Response (A MYELOMATCH Treatment Trial)RecruitingPhase 2National Cancer Institute (NCI)NCT06917911Written as Gemtuzumab Ozogamicin
- Fludarabine Phosphate, Cytarabine, Filgrastim-sndz, Gemtuzumab Ozogamicin, and Idarubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic SyndromeRecruitingPhase 2M.D. Anderson Cancer CenterNCT00801489Written as Gemtuzumab Ozogamicin
- Fractionated Gemtuzumab Ozogamicin in Treating Measurable Residual Disease in Patients With Acute Myeloid LeukemiaRecruitingPhase 2University of WashingtonNCT03737955Written as Gemtuzumab Ozogamicin
- CLAG-GO for Patients With Persistent, Relapsed or Refractory AMLRecruitingPhase 2University of Maryland, BaltimoreNCT04050280Written as Cladribine, Cytarabine, and Granulocyte-Colony Stimulating Factor with Fractionated Gemtuzumab Ozogamicin (CLAG-GO)
- A Phase I Study Investigating the Combination of the Menin Inhibitor Ziftomenib With Venetoclax and Gemtuzumab in Pediatric Patients With Acute Myeloid LeukemiaRecruitingPhase 1M.D. Anderson Cancer CenterNCT06448013Written as Gemtuzumab
- Tretinoin and Arsenic Trioxide With or Without Gemtuzumab Ozogamicin in Treating Patients With Previously Untreated Acute Promyelocytic LeukemiaRecruitingPhase 2M.D. Anderson Cancer CenterNCT01409161Written as Gemtuzumab Ozogamicin
- CPX-351 in Combination With Gemtuzumab Ozogamicin in Newly Diagnosed AMLRecruitingPhase 1H. Lee Moffitt Cancer Center and Research InstituteNCT05558124Written as Gemtuzumab Ozogamicin
- Combination of Midostaurin and Gemtuzumab Ozogamicin in First-line Standard Therapy for Acute Myeloid Leukemia (MOSAIC)RecruitingPhase 1/2Technische Universität DresdenNCT04385290Written as MAGNOLIA-trial: conventional chemotherapy (AraC+DNR)+GO
- Gemtuzumab Chemotherapy MRD Levels; Adult Untreated, de Novo, Fav Interm Risk AMLRecruitingPhase 3Gruppo Italiano Malattie EMatologiche dell'AdultoNCT04168502Written as Gemtuzumab Ozogamicin
- Treatment Study for Children and Adolescents With Acute Promyelocytic LeukemiaRecruitingPhase 2Associazione Italiana Ematologia Oncologia PediatricaNCT04793919Written as Mylotarg
- Azacitidine and Gemtuzumab Ozogamicin in Treating Older Patients With Previously Untreated Acute Myeloid LeukemiaActive, not recruitingPhase 2National Cancer Institute (NCI)NCT00658814Written as Gemtuzumab Ozogamicin
- Liposome-encapsulated Daunorubicin-Cytarabine and Gemtuzumab Ozogamicin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) or High Risk Myelodysplastic SyndromeCompletedPhase 2M.D. Anderson Cancer CenterNCT03672539Written as Gemtuzumab Ozogamicin
- Fractionated Gemtuzumab Ozogamicin Followed by Non-engraftment Donor Leukocyte Infusions for Relapsed/Refractory Acute Myeloid LeukemiaCompletedPhase 1/2Brown UniversityNCT03374332Written as Gemtuzumab Ozogamicin (GO)
- International Randomised Phase III Clinical Trial in Children With Acute Myeloid LeukaemiaActive, not recruitingPhase 3University of BirminghamNCT02724163Written as Gemtuzumab ozogamicin
- Tagraxofusp-erzs, an IL-3 Diphtheria Fusion Protein, in Combination With Gemtuzumab Ozogamicin in Patients With Relapsed/Refractory AMLTerminatedPhase 1Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsNCT05716009Written as Dose Escalation -tagraxofusp-erzs
- Liposomal Cytarabine, Daunorubicin, and Gemtuzumab Ozogamicin for the Treatment of Relapsed Refractory Pediatric Patients With Acute Myeloid LeukemiaCompletedPhase 1M.D. Anderson Cancer CenterNCT04915612Written as Gemtuzumab Ozogamicin
- Gentuzumab Ozogamicin and Midostaurin Combination With Standard Cytarabine and Danunorubi Midostaurin as a Novel Approach to Treating Patients With Newly Diagnosed FLT-3 Mutated Acute Myeloid LeukemiaCompletedPhase 1Uma BorateNCT03900949Written as Gemtuzumab Ozogamicin
- Allogeneic Engineered Hematopoietic Stem Cell Transplant (HCT) Lacking the CD33 Protein, and Post-HCT Treatment With Mylotarg, for Patients With CD33+ AML or MDSTerminatedPhase 1/2Vor BiopharmaNCT04849910Written as Mylotarg
- Study of the Safety and Efficacy of Gemtuzumab Ozogamicin (GO) and Venetoclax in Patients With Relapsed or Refractory CD33+ Acute Myeloid Leukemia:Big Ten Cancer Research Consortium BTCRC-AML17-113CompletedPhase 1John QuigleyNCT04070768Written as Gemtuzumab Ozogamicin
- Phase II Study of the Combination of Mitoxantrone, Etoposide and Gemtuzumab Ozogamicin (MEGO) for Patients With Acute Myeloid Leukemia Refractory to Initial Standard Induction TherapyCompletedPhase 2Robert Redner, MDNCT03839446Written as mitoxantrone + etoposide + gemtuzumab ozogamicin
See all 73 studies that test Gemtuzumab →
Given in every arm · 13 — Gemtuzumab is usual care beside what is tested
- A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 MutationsRecruitingPhase 3Children's Oncology GroupNCT04293562Written as Gemtuzumab Ozogamicin
- A Study of Venetoclax in Combination With Conventional Chemotherapy in Pediatric Patients With Acute Myeloid LeukemiaRecruitingPhase 2St. Jude Children's Research HospitalNCT05955261Written as Gemtuzumab Ozogamicin
- Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)RecruitingPhase 3PedAL BCU, LLCNCT05183035Written as Gemtuzumab Ozogamicin
- Dexrazoxane Hydrochloride in Preventing Heart-Related Side Effects of Chemotherapy in Participants With Blood CancersRecruitingPhase 2M.D. Anderson Cancer CenterNCT03589729Written as Gemtuzumab Ozogamicin
- Genetic Ablation of CD33 in HSC to Broaden the Therapeutic Index of CD33-directed Immunotherapy in Patients with AMLNot yet recruitingPhase 1German Cancer Research CenterNCT05662904Written as Gemtuzumab Ozogamicin
- Vyxeos for Induction of Low- or Intermediate-risk.Active, not recruitingPhase 2Shaare Zedek Medical CenterNCT05599360Written as Mylotarg
- Atovaquone (Mepron®) Combined With Conventional Chemotherapy for de Novo Acute Myeloid Leukemia (AML)CompletedEarly Phase 1Baylor College of MedicineNCT03568994Written as Gemtuzumab Ozogamicin
- Combination Chemotherapy With or Without Monoclonal Antibody Therapy in Treating Patients With AML LeukemiaCompletedPhase 3Eastern Cooperative Oncology GroupNCT00049517Written as gemtuzumab ozogamicin (GO)
- TEAM-Trial: Targeting Epigenetic Therapy Resistance in AML With BortezomibCompletedPhase 2University Hospital HeidelbergNCT04173585Written as Gemtuzumab Ozogamicin
- CPX-351+GO in Subjects 55 Years Old, or Older, With AMLTerminatedPhase 1Weill Medical College of Cornell UniversityNCT03878927Written as Gemtuzumab Ozogamicin
- AflacLL1901 (CHOA-AML)TerminatedPhase 2Emory UniversityNCT04326439Written as Gemtuzumab ozogamicin
- All-trans Retinoic Acid, and Arsenic +/- IdarubicinCompletedPhase 2M.D. Anderson Cancer CenterNCT00413166Written as Gemtuzumab Ozogamicin
- Gemtuzumab Ozogamicin and High-Dose Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid LeukemiaCompletedPhase 2Alliance for Clinical Trials in OncologyNCT00006265Written as gemtuzumab ozogamicin
As the comparator · 2 — what is tested is compared with Gemtuzumab
- MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)RecruitingPhase 2National Cancer Institute (NCI)NCT05564390Written as Gemtuzumab Ozogamicin
- SCH 727965 in Patients With Acute Myelogenous Leukemia and Acute Lymphoblastic Leukemia (P04717AM2)(TERMINATED)TerminatedPhase 2Merck Sharp & Dohme LLCNCT00798213Written as Gemtuzumab ozogamicin
Codes
What other systems call Gemtuzumab · ClinicalTrials.gg INT006840
- MeSH (NLM) D000079982GemtuzumabConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) 93NS566KF7GEMTUZUMABConfirmed FDA, NLM, Wikidata
- Wikidata Q105946712gemtuzumabConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C171025GemtuzumabOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | D000079982 | Gemtuzumab | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | 93NS566KF7 | GEMTUZUMAB | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q105946712 | gemtuzumab | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C171025 | Gemtuzumab | One source FDA |
Also registered as gemtuzumab ozogamicin (UNII 8GZG754X6M · RxNorm 1294580).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.